abstract |
The present invention is an allosteric modulator of metabotropic glutamate receptors, including the mGluR5 receptor, and the treatment of neurological and psychiatric disorders related to glutamate dysfunction and diseases involving metabotropic glutamate receptors The compounds useful for the above are intended. The present invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases involving metabotropic glutamate receptors. |